Celldex Therapeutics Inc (CLDX)
NASDAQ:CLDX
Want to see CLDX full AI Analyst Report?
CLDX Stock Chart & Stats
$34.55
-$0.90(-3.26%)
At close: 4:00 PM EST
$34.55
-$0.90(-3.26%)
Day’s Range― - ―
52-Week Range$18.20 - $35.79
Previous CloseN/A
Volume733.18K
Average Volume (3M)1.17M
Market Cap
$2.61B
Enterprise Value$2.23B
Total Cash (Recent Filing)$518.57M
Total Debt (Recent Filing)$2.34M
Price to Earnings (P/E)―
Beta1.21
Next Earnings
Aug 06, 2026EPS Estimate
-1.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.90
Shares Outstanding78,463,100
10 Day Avg. Volume1,192,680
30 Day Avg. Volume1,174,794
Financial Highlights & Ratios
PEG Ratio-0.12
Price to Book (P/B)3.43
Price to Sales (P/S)1204.09
P/FCF Ratio-8.45
Enterprise Value/Market Cap0.85
Enterprise Value/Revenue1.49K
Enterprise Value/Gross Profit1.49K
Enterprise Value/Ebitda-8.01
Forecast
1Y Price Target
$57.00Price Target Upside64.98% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)-4.76
Revenue Forecast (FY)$2.85M
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy And DurabilityPhase 2 results showing strong efficacy, durable symptom improvement after treatment cessation, and restoration of control on re-treatment suggest a differentiated clinical profile that could drive physician and patient adoption.
Clinical Trial EnrollmentCompletion of enrollment in two pivotal Phase 3 chronic spontaneous urticaria trials ahead of guidance demonstrates strong patient and investigator interest and positions upcoming top-line readouts as major catalysts.
Pipeline DiversificationInitiation of early-stage studies for CDX-622 and a bispecific antibody program, together with multiple Phase 2 and Phase 3 dermatology programs, broadens development pathways and creates several independent value drivers.
Bears Say
Cash Runway And Financing RiskLimited cash runway at current spending levels creates a financing risk that could necessitate equity issuance and dilute existing shareholders if additional funding is required.
Financial Performance And Cost PressureReported earnings per share missed analyst expectations and operating expenses came in higher than projected, highlighting near-term financial pressure that could constrain strategic flexibility.
Market Skepticism And Competitive LandscapeNotable short interest combined with an evolving standard of care and competing clinical programs increases selling pressure and could limit commercial uptake even after regulatory approval.
Celldex News
CLDX FAQ
What was Celldex Therapeutics Inc’s price range in the past 12 months?
Celldex Therapeutics Inc lowest stock price was $18.20 and its highest was $35.79 in the past 12 months.
What is Celldex Therapeutics Inc’s market cap?
Celldex Therapeutics Inc’s market cap is $2.61B.
When is Celldex Therapeutics Inc’s upcoming earnings report date?
Celldex Therapeutics Inc’s upcoming earnings report date is Aug 06, 2026 which is in 89 days.
How were Celldex Therapeutics Inc’s earnings last quarter?
Celldex Therapeutics Inc released its earnings results on May 07, 2026. The company reported -$1.18 earnings per share for the quarter, missing the consensus estimate of -$1.15 by -$0.03.
Is Celldex Therapeutics Inc overvalued?
According to Wall Street analysts Celldex Therapeutics Inc’s price is currently Undervalued.
Does Celldex Therapeutics Inc pay dividends?
Celldex Therapeutics Inc does not currently pay dividends.
What is Celldex Therapeutics Inc’s EPS estimate?
Celldex Therapeutics Inc’s EPS estimate is -1.05.
How many shares outstanding does Celldex Therapeutics Inc have?
Celldex Therapeutics Inc has 78,463,100 shares outstanding.
What happened to Celldex Therapeutics Inc’s price movement after its last earnings report?
Celldex Therapeutics Inc reported an EPS of -$1.18 in its last earnings report, missing expectations of -$1.15. Following the earnings report the stock price went down -3.111%.
Which hedge fund is a major shareholder of Celldex Therapeutics Inc?
Currently, no hedge funds are holding shares in CLDX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Celldex Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$57.00 (64.98% Upside)
$57.00 (64.98% Upside)
Blogger Sentiment
Bullish
CLDX Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 310.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 9.9%
Last 30 Days ▲ 9.9%
Technicals
SMA
Positive
20 days / 200 days
Momentum
88.79%
12-Months-Change
Fundamentals
Return on Equity
-50.72%
Trailing 12-Months
Asset Growth
-26.42%
Trailing 12-Months
Company Description
Celldex Therapeutics Inc
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation. The company has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University. Celldex Therapeutics, Inc. was incorporated in 1983 and is headquartered in Hampton, New Jersey.
CLDX Stock 12 Month Forecast
Average Price Target
$57.00
▲(64.98% Upside)
Technical Analysis
Travere Therapeutics
―
Viridian Therapeutics
―
―
Vera Therapeutics
―
Janux Therapeutics Inc
―
Ownership Overview
0.30% Insiders
24.82% Mutual Funds
2.90% Other Institutional Investors
59.82% Public Companies and
Individual Investors